MX2019003171A - Sales de adicion de acido de derivado de benzimidazol. - Google Patents

Sales de adicion de acido de derivado de benzimidazol.

Info

Publication number
MX2019003171A
MX2019003171A MX2019003171A MX2019003171A MX2019003171A MX 2019003171 A MX2019003171 A MX 2019003171A MX 2019003171 A MX2019003171 A MX 2019003171A MX 2019003171 A MX2019003171 A MX 2019003171A MX 2019003171 A MX2019003171 A MX 2019003171A
Authority
MX
Mexico
Prior art keywords
acid addition
addition salt
benzimidazole derivative
stability
phase stability
Prior art date
Application number
MX2019003171A
Other languages
English (en)
Inventor
Ah LEE Sung
Do Choi Kwang
Sun Kim Eun
Kyoung Lee Min
Sun Kim Jae
Chul Yoo Hyung
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of MX2019003171A publication Critical patent/MX2019003171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una sal de pidolato y una sal de malato de un compuesto representado por una fórmula 1 con una excelente estabilidad de fase líquida, estabilidad de fase sólida, solubilidad en agua, estabilidad de precipitación e higroscopicidad en conjunto como un compuesto para prevenir y tratar enfermedades mediadas por una actividad antagonística de bomba de ácido, así como un procedimiento para preparar la misma.
MX2019003171A 2016-09-21 2017-09-20 Sales de adicion de acido de derivado de benzimidazol. MX2019003171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160120996A KR101829706B1 (ko) 2016-09-21 2016-09-21 벤즈이미다졸 유도체의 산부가염
PCT/KR2017/010332 WO2018056697A1 (ko) 2016-09-21 2017-09-20 벤즈이미다졸 유도체의 산부가염

Publications (1)

Publication Number Publication Date
MX2019003171A true MX2019003171A (es) 2019-06-10

Family

ID=61387666

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003171A MX2019003171A (es) 2016-09-21 2017-09-20 Sales de adicion de acido de derivado de benzimidazol.

Country Status (13)

Country Link
US (3) US11535610B2 (es)
EP (1) EP3517528B1 (es)
JP (1) JP6814891B2 (es)
KR (1) KR101829706B1 (es)
CN (1) CN109769392B (es)
AR (1) AR109679A1 (es)
ES (1) ES2896802T3 (es)
JO (1) JOP20170172B1 (es)
MX (1) MX2019003171A (es)
MY (1) MY197242A (es)
PH (1) PH12019500602A1 (es)
TW (1) TWI659028B (es)
WO (1) WO2018056697A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200024413A (ko) * 2018-08-28 2020-03-09 에이치케이이노엔 주식회사 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물
JOP20190201A1 (ar) * 2018-08-29 2020-02-29 Hk Inno N Corp تركيبة لاستئصال الملوية البوابية
EP3927340A4 (en) * 2019-02-18 2022-11-02 HK inno.N Corporation PHARMACEUTICAL COMPOSITION WITH BENZIMIDAZOLE DERIVATIVE COMPOUND
CA3182245A1 (en) * 2020-06-12 2021-12-16 Jae Hee Cheon Pharmaceutical composition comprising benzimidazole derivative compound
WO2022086238A1 (en) * 2020-10-23 2022-04-28 Hk Inno.N Corporation Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof
TWI822151B (zh) * 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
WO2023106842A1 (ko) * 2021-12-08 2023-06-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도
KR20230114163A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
ATE442140T1 (de) 2005-06-14 2009-09-15 Raqualia Pharma Inc Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
EP1963311B1 (en) * 2005-12-19 2010-06-16 RaQualia Pharma Inc Chromane substituted benzimidazoles and their use as acid pump inhibitors
EP2318411A2 (en) 2008-07-03 2011-05-11 Ratiopharm GmbH Crystalline salts of sitagliptin
TW201920110A (zh) * 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
KR101605063B1 (ko) 2009-07-09 2016-03-21 라퀄리아 파마 인코포레이티드 소화관 운동이상이 관여하는 질환의 치료용 산 펌프 길항제
KR101684053B1 (ko) 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
KR102262743B1 (ko) 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물

Also Published As

Publication number Publication date
KR101829706B1 (ko) 2018-02-19
US11535610B2 (en) 2022-12-27
CN109769392B (zh) 2022-06-24
US20230192670A1 (en) 2023-06-22
TWI659028B (zh) 2019-05-11
JOP20170172B1 (ar) 2022-03-14
EP3517528A1 (en) 2019-07-31
TW201815786A (zh) 2018-05-01
BR112019005505A2 (pt) 2019-06-04
ES2896802T3 (es) 2022-02-25
US20240150331A1 (en) 2024-05-09
MY197242A (en) 2023-06-07
EP3517528A4 (en) 2020-05-20
WO2018056697A1 (ko) 2018-03-29
JOP20170172A1 (ar) 2019-01-30
JP2019529557A (ja) 2019-10-17
JP6814891B2 (ja) 2021-01-20
US20210292307A1 (en) 2021-09-23
AR109679A1 (es) 2019-01-09
CN109769392A (zh) 2019-05-17
PH12019500602A1 (en) 2019-11-11
US11912690B2 (en) 2024-02-27
EP3517528B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
PH12019500602A1 (en) Acid additional salt of benzimidazole derivative
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
MX2019003747A (es) Compuesto de piridina.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MD20160017A2 (ro) Polimorf al inhibitorilor SYK
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
WO2016077464A8 (en) Amino acid derivatives and their uses
EA201490747A1 (ru) 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний
EA201792071A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201891770A1 (ru) Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм
MX348977B (es) Preparación de sales de guanidina bicíclica en un medio acuoso.
PH12016501175A1 (en) Formulations of deoxycholic acid and salts thereof
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX2016010564A (es) Procesos para preparar moduladores del canal ionico heterociclico fusionado.
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
MX358669B (es) Croman-6-iloxi-cicloalcanos sustituidos y su uso como productos farmaceuticos.
PH12018501046A1 (en) Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and method for producing said crystals
EA202090438A1 (ru) Производные глицерретиновой кислоты для лечения гиперкалиемии
TN2014000106A1 (en) Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
PL410425A1 (pl) Nowe alkoksymetylodi(2-hydroksyetylo)metyloamoniowe ciecze jonowe z słodkim anionem oraz sposób ich wytwarzania
AR119050A2 (es) Compuestos del ácido 3,6-diclorosalicílico y procesos de síntesis relacionados

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: YUNGJIN PHARM. CO., LTD.